To identify the molecular mechanism underlying gliobastoma resistance to anti-VEGF therapy, we treated GSC11 glioma–bearing mice with or without bevacizumab until the mice became moribund (2 mice per group). This evidence concerns the gene VEGFA and central nervous system cancer.